Discontinuation of anti‑programmed cell death protein 1 immune checkpoint inhibition after complete remission in head and neck squamous cell carcinoma: A case report and literature review-Reference-Cited by-同舟云学术

Discontinuation of anti‑programmed cell death protein 1 immune checkpoint inhibition after complete remission in head and neck squamous cell carcinoma: A case report and literature review

Published:2023-09-27 Issue:5 Volume:26 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Stöth Manuel¹,Meyer Till¹,Gehrke Thomas¹,Hagen Rudolf¹,Scheich Matthias¹,Hackenberg Stephan²,Scherzad Agmal¹

Affiliation:

1. Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University Hospital Würzburg, D‑97080 Würzburg, Germany

2. Department of Otorhinolaryngology‑Head and Neck Surgery, University Hospital, Rhine‑Westphalia Technical University of Aachen, D‑52074 Aachen, Germany

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference36 articles.

1. Head and neck squamous cell carcinoma;Johnson;Nat Rev Dis Primers,2020

2. Risk factors in head and neck cancer;Decker;N Engl J Med,1982

3. Papillomaviruses in the causation of human cancers-a brief historical account;zur Hausen;Virology,2009

4. Head and neck cancer;Forastiere;N Engl J Med,2001

5. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation;Cancers;2024-07-12

2. Cisplatin/Docetaxel;Reactions Weekly;2024-01-20